Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
Location: United States, Pennsylvania, Pittsburgh
Total raised: $425M
Investors 5
| Date | Name | Website |
| - | Population... | population... |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | Access Bio... | accessbio-... |
| 09.08.2022 | GV | gv.com |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.02.2024 | Series A | $75M | - |
| 13.07.2022 | - | $350M | Bain Capit... |
Mentions in press and media 6
| Date | Title | Description |
| 20.02.2024 | Areteia Therapeutics Secures $75M Boost in Series A Funding | Areteia Therapeutics, a biotech company based in Chapel Hill, NC, has clinched an additional $75 million in Series A financing. This injection of funds brings their total funding to a staggering $425 million. The round of funding was backed... |
| 14.02.2024 | Areteia Therapeutics Raises Additional $75M in Series A Financing | Areteia Therapeutics, a Chapel Hill, NC-based clinical stage biotechnology company, raised additional $75M in Series A funding. The round, which brought the total amount to $425M, saw support from Viking Global Investors and Marshall Wace, ... |
| 13.02.2024 | Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma | - |
| 13.02.2024 | Areteia Therapeutics Lands Additional $75M | CHAPEL HILL, NC, Areteia Therapeutics today announced $75 million in additional Series A financing. >> Click here for more funding data on Areteia Therapeutics >> To export Areteia Therapeutics funding data to PDF and Excel,... |
| 18.05.2023 | Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma | CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics announced today that the first patients have been dosed in both the EXHALE-2 and EXHALE-4 trials as part of its overall Phase III clinical program investigating the efficacy and safety ... |
| - | Areteia Therapeutics | “Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.” |